ArticleMultiple sclerosis journal - experimental, translational and clinical
Use of optical coherence tomography in the care of people with multiple sclerosis in Switzerland: A national survey among neurologists.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optical coherence tomography (OCT) can assess optic nerve involvement and facilitate the diagnosis of multiple sclerosis (MS). Objective: To evaluate the current use of OCT for MS care among neurologists in Switzerland. Methods: Nationwide online survey with Swiss neurologists, comprising 11 questions on availability, use of OCT, and its role in diagnostic workup and monitoring. Results: Thirty-four neurologists from all main Swiss regions responded (53% hospital-based, 47% private practice). Only 26.5% had access to OCT in their clinic/practice, all of whom were MS specialists, mainly hospital-based (66.7%). All respondents assess the visual pathway in first demyelinating event and optic neuritis (ON), primarily using magnetic resonance imaging (MRI: 88.2% and 91.2%, respectively), often in combination with visual evoked potentials (VEP). OCT use was reported by 32% (first demyelinating event) and 44% (ON) of respondents. OCT was infrequently used for monitoring (20.6%), the most frequent reasons being "lack of availability" or "insufficient evidence." Conclusions: Despite the scientific evidence, OCT availability and routine use by neurologists is limited in Switzerland. Awareness, education and guidelines on its clinical use in MS care are needed, while ongoing real-world research should shed more light into its role for personalized disease monitoring in people with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.